SKB264 tumor-growth inhibition
A reduced tumor-growth model representing the balance between untreated tumor expansion and SKB264-associated tumor-cell killing.
- Therapeutic
- SKB264 (sacituzumab tirumotecan), anti-TROP2 humanized mAb shared with IMMU-132
- Target
- TACSTD2, TROP2, EGP1
- Disease
- Ocular disease
Biological model
A reduced tumor-growth model representing the balance between untreated tumor expansion and SKB264-associated tumor-cell killing.
Intervention
SKB264 (sacituzumab tirumotecan), anti-TROP2 humanized mAb shared with IMMU-132
Biological focus
TACSTD2, TROP2, EGP1
Context
Ocular disease
Model details
A reduced tumor-growth model representing the balance between untreated tumor expansion and SKB264-associated tumor-cell killing.
Modeled states
- tumor volume mm3millimeter**3
Modeled dynamic state for tumor volume mm3.
Key readouts
- Tumor volumemillimeter**3
Model-derived readout for tumor volume.
- Net tumor growth rateunknown
Model-derived readout for net tumor growth rate.
- tumor growth rate dayunknown
Model-derived readout for tumor growth rate day.
- tumor kill rate dayunknown
Model-derived readout for tumor kill rate day.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Default model behavior
How does the modeled ADC killing rate change tumor-volume dynamics relative to intrinsic growth? Explore this biological starting configuration through Tumor volume, Net tumor growth rate. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How does the modeled ADC killing rate change tumor-volume dynamics relative to intrinsic growth?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How does the modeled ADC killing rate change tumor-volume dynamics relative to intrinsic growth?
tumor growth rate day
Model parameter controlling tumor growth rate day.
Exploratory range around the default value.
5 evenly spaced values in 1/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132Frontiers in Oncology
